Covidien Public Limited Company is a healthcare products company. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company's brands include Kendall, Nellcor, Puritan Bennett and Valleylab, among others. It has a presence in more than 70 countries, with products sold in over 150 countries. The Company's segments include Medical Devices and United States Medical Supplies. Medical Devices includes marketing of advanced and general surgical solutions, peripheral vascular and neurovascular therapies, patient monitoring products, and airway and ventilation products. United States Medical Supplies includes products, such as nursing care, medical surgical, SharpSafety and original equipment manufacturer (OEM) products. The Company's products include Surgical Solutions, Vascular Therapies, Respiratory and Patient Care.
Industry, Sector and Symbol:
- Industry: Health Care Equipment & Supplies
- Sub-Industry: Health Care Equipment
- Symbol: NYSE:COV
- CUSIP: G2554F11
- Web: N/A
- Trailing P/E Ratio: N/A
- P/E Growth: 0
Frequently Asked Questions for Covidien Ltd (NYSE:COV)
What is Covidien Ltd's stock symbol?
Covidien Ltd trades on the New York Stock Exchange (NYSE) under the ticker symbol "COV."
How were Covidien Ltd's earnings last quarter?
Covidien Ltd (NYSE:COV) released its earnings results on Wednesday, November, 5th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.13. The business had revenue of $2.73 billion for the quarter, compared to analysts' expectations of $2.69 billion. The business's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.91 EPS. View Covidien Ltd's Earnings History.
Who are some of Covidien Ltd's key competitors?
Some companies that are related to Covidien Ltd include Merck KGaA (MKGAY), Hospira (HSP), Omnicare (OCR), Health Net (HNT), WuXi PharmaTech (Cayman) (WX), Hanger (HGR), SIGA Technologies (SIGA), Nobilis Health Corp (HLTH), Verastem (VSTM), Palatin Technologies (PTN), KaloBios Pharmaceuticals (KBIO), AdCare Health Systems (ADK), Capricor Therapeutics (CAPR), 3SBio (SSRX), Alexza Pharmaceuticals (ALXA), Allergan plc (WPI), Allergan plc (ACT) and Allos Therapeutics (ALTH).
How do I buy Covidien Ltd stock?
Shares of Covidien Ltd can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Covidien Ltd's stock price today?
MarketBeat Community Rating for Covidien Ltd (NYSE COV)MarketBeat's community ratings are surveys of what our community members think about Covidien Ltd and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Covidien Ltd stock can currently be purchased for approximately $108.07.
Consensus Ratings for Covidien Ltd (NYSE:COV) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Covidien Ltd (NYSE:COV)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Covidien Ltd (NYSE:COV)Earnings History by Quarter for Covidien Ltd (NYSE COV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|1/22/2015||Q115||$1.04||$1.11||$2.72 billion||$2.69 billion||View||N/A|
|11/5/2014||Q414||$1.02||$1.15||$2.69 billion||$2.73 billion||View||Listen|
|7/25/2014||Q314||$1.00||$1.04||$2.69 billion||$2.69 billion||View||Listen|
|4/25/2014||Q214||$0.95||$0.96||$2.61 billion||$2.60 billion||View||Listen|
|1/24/2014||Q114||$0.94||$1.00||$2.61 billion||$2.64 billion||View||Listen|
|8/1/2013||Q3 2013||$0.89||$0.85||$2.58 billion||$2.58 billion||View||Listen|
|4/26/2013||Q2 2013||$1.09||$1.12||$3.12 billion||$3.10 billion||View||Listen|
|1/25/2013||Q1 2013||$1.06||$1.10||$3.00 billion||$3.06 billion||View||Listen|
|11/9/2012||Q412||$1.00||$1.02||$2.98 billion||$3.00 billion||View||N/A|
Earnings Estimates for Covidien Ltd (NYSE:COV)
Current Year EPS Consensus Estimate: $0.00 EPS
Next Year EPS Consensus Estimate: $0.00 EPS
Current Dividend Information for Covidien Ltd (NYSE:COV)
|Most Recent Dividend:||1/16/2015|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||NaN (Based on This Year's Estimates)|
NaN (Based on Next Year's Estimates)
|Track Record:||8 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Covidien Ltd (NYSE COV)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Covidien Ltd (NYSE:COV)Insider Trades by Quarter for Covidien Ltd (NYSE:COV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/5/2014||Michael Sgrignari||SVP||Sell||25,795||$103.48||$2,669,266.60|| |
|12/3/2014||Dennis H Reilley||Director||Sell||10,521||$101.39||$1,066,724.19|| |
|11/17/2014||Richard G Brown Jr||VP||Buy||5,300||$94.44||$500,532.00|| |
|11/7/2014||Robert H Brust||Director||Sell||4,000||$92.03||$368,120.00|| |
|8/27/2014||Coleman N Lannum III||VP||Buy||3,338||$87.23||$291,173.74|| |
|8/26/2014||Coleman N Lannum III||VP||Buy||1,736||$87.46||$151,830.56|| |
|8/19/2014||Coleman N Lannum III||VP||Buy||1,720||$87.82||$151,050.40|| |
|8/18/2014||Coleman N Lannum III||VP||Buy||4,100||$87.58||$359,078.00|| |
|6/16/2014||Jose E Almeida||Insider||Sell||51,166||$92.05||$4,709,830.30|| |
|4/29/2014||Brian Douglas King||VP||Sell||15,569||$70.11||$1,091,542.59|| |
|3/28/2014||Charles Dockendorff||CFO||Sell||90,730||$72.50||$6,577,925.00|| |
|2/28/2014||Jose Almeida||Insider||Sell||50,000||$72.00||$3,600,000.00|| |
|2/13/2014||Richard Brown, Jr.||VP||Sell||4,000||$71.00||$284,000.00|| |
|2/11/2014||Brian Douglas King||VP||Sell||17,946||$70.00||$1,256,220.00|| |
|2/11/2014||Bryan Hanson||SVP||Sell||32,480||$69.97||$2,272,625.60|| |
|1/29/2014||Coleman Lannum III||VP||Sell||13,787||$69.23||$954,474.01|| |
|1/24/2014||Richard Brown, Jr.||VP||Sell||4,000||$70.00||$280,000.00|| |
Headline Trends for Covidien Ltd (NYSE:COV)
Latest Headlines for Covidien Ltd (NYSE:COV)
Covidien Ltd (COV) Chart for Tuesday, May, 30, 2017